These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1578709)

  • 1. [Treatment of hyperlipoproteinemia by plasma exchange].
    Homma Y
    Nihon Rinsho; 1992 Jan; 50 Suppl():370-3. PubMed ID: 1578709
    [No Abstract]   [Full Text] [Related]  

  • 2. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: prevalence and precipitating factors.
    Lowry RP; Soltys G; Mangel R; Kwiterovitch P; Sniderman AD
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2229-32. PubMed ID: 3547921
    [No Abstract]   [Full Text] [Related]  

  • 3. [Plasma exchange therapy in a patient with familial hypercholesteremia and generalized arteriosclerosis].
    Schrecker O; Thies K; Schlierf G
    Internist (Berl); 1984 Sep; 25(9):574-6. PubMed ID: 6386739
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hyperlipoproteinemia--problems of diagnosis and treatment. Report of the Working Group of the Polish Cardiology Society].
    Michajlik A; Ciświcka-Sznajderman M; Sznajd J; Szostak W
    Kardiol Pol; 1982; 25(12):1061-8. PubMed ID: 7169735
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dyslipoproteinemia as a coronary risk factor].
    Yamamura T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():738-45. PubMed ID: 12735059
    [No Abstract]   [Full Text] [Related]  

  • 6. [Direct quantitative determination of LDL cholesterol and HDL cholesterol using agarose gel electrophoresis].
    Herrmann W; Hanf S; Schütz C; Thomas H
    Z Gesamte Inn Med; 1984 Oct; 39(19):478-81. PubMed ID: 6516489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rationale for setting target plasma lipid levels to reverse atherosclerosis.
    Parker TS; Saal SD; Gordon BR; Tyberg TI; Levine DM; Rubin AL
    Beitr Infusionsther; 1988; 23():132-7. PubMed ID: 2484767
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hyperlipoproteinemia in the production of atherosclerosis. Risk factors: diagnosis and treatment].
    Pedraza A
    Rev Fac Cien Med Univ Nac Cordoba; 1993; 51(1):21-33. PubMed ID: 7809452
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of hyperlipoproteinemia].
    Drexel H; Follath F
    Schweiz Rundsch Med Prax; 1993 Apr; 82(17):506-9. PubMed ID: 8493437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperlipoproteinemia as the cause of increased plasma antiheparin activity in patients with arteriosclerosis].
    Rółkowski R; Worowski K; Skrzydlewski Z; Głowiński S
    Kardiol Pol; 1986; 29(3):204-8. PubMed ID: 3773409
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 12. [New results of studies of plasma lipoprotein metabolism and the pathogenesis of hyperlipoproteinemias].
    Szollár L
    Orv Hetil; 1984 Oct; 125(43):2599-609. PubMed ID: 6493768
    [No Abstract]   [Full Text] [Related]  

  • 13. [Arteriosclerosis. IV. Treatment of dyslipoproteinemia].
    Cybulska B; Kłosiewicz-Latoszek L
    Wiad Lek; 1985 Sep; 38(17):1251-7. PubMed ID: 4090499
    [No Abstract]   [Full Text] [Related]  

  • 14. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
    Sznajderman M; Zawadzki Z
    Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
    [No Abstract]   [Full Text] [Related]  

  • 15. Can genes prevent atherosclerosis?
    Hoeg JM
    JAMA; 1996 Sep; 276(12):989-92. PubMed ID: 8805735
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dietary treatment of hyperlipoproteinemia. Reduction of atherogenic lipid fractions in normal subjects].
    Weisweiler P
    Fortschr Med; 1985 Feb; 103(7):148-50. PubMed ID: 3972329
    [No Abstract]   [Full Text] [Related]  

  • 17. [In vivo effects of high density lipoprotein rich serum fractions (HDLF) in the human. 2. Effect of repeated HDLF infusions on atherogenic risk factors and arteriosclerotic vascular changes in patients with and without hyperlipoproteinemia].
    Kuklinski B; Parfionov AS; Rühlmann C; Zimmermann R; Herrmann W; Richter V; Köhler H; Grossmann KD; Peters HJ; Duck HJ
    Z Gesamte Inn Med; 1989 Jul; 44(14):421-6. PubMed ID: 2683424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperapobetalipoproteinaemia: an emerging risk factor for atherosclerosis.
    Thompson GR; Trayner IA; Allaway SL; Robinson D; Ritchie CD
    Monogr Atheroscler; 1986; 14():129-31. PubMed ID: 3736551
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of jejunoileoshunting on hyperlipoproteinemia in patients with pathologic obesity].
    Sedletskiĭ IuI
    Klin Khir (1962); 1985 Feb; (2):13-5. PubMed ID: 3857390
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute lipidemic effect of calcium heparin in normolipemic and hyperlipemic subjects.
    Ferlito S; Ricceri M; Ossino AM
    Int Angiol; 1989; 8(3):140-4. PubMed ID: 2592796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.